Program
Gallium Ga 68 NNS309
In Novartis’s pipeline, Radioligand therapy target FAP
. Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Novartis.
Furthest: phase 1, since Nov 21, 20252 company-led studies, 2 open or runningNext primary completion: Jan 16, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 22 open or running | phase 1since Nov 21, 2025 | Nov 21, 2025 | Jan 16, 2028phase 1 · NCT07630961 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 21, 2025First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07261631 · 180 planned · United States, Canada, Denmark and more
- Jun 1, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07630961 · 66 planned · Denmark, Japan
Ahead
- Jan 16, 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07630961
- May 9, 2029Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07261631
TargetBeta
“Radioligand therapy target FAP”the company's pipeline, read by Claude · source
Other programs on FAP
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lutetium-177 | Novartis | phase 3 | 24 |
| Gallium-68 | Philogen | phase 3 | 17 |
| Fluorine F 18 FAPI-74rule | sofie | phase 3 | 3 |
| Fluorine F 18 FPyQCPrule | Bracco | phase 2 | 1 |
| HRS-6768 | Jiangsu HengRui Medicine | phase 2 | 1 |
| Anti-FAP Antibody-drug Conjugate OMTX705rule | oncomatryx-biopharma-s-l | phase 1 | 2 |
| Actinium Ac 225 RTX-2358rule | ratio-therapeutics-inc | phase 1 | 1 |
| Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713rule | Eli Lilly | phase 1 | 1 |
| Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050rule | Immunome | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07630961Carcinoma, Non-Small-Cell Lung · Denmark, Japan | 1 | Recruiting | Jan 16, 2028 | 66 |
| NCT07261631Carcinoma, Non-Small-Cell Lung · United States, Canada, Denmark and more | 1 | Recruiting | May 9, 2029 | 180 |
How it is read
Names in the registry
- “68Ga-NNS309”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.